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Abstract
Background: Heart failure (HF) and sleep apnoea (SA) association has been recognized but whether it results from
confounding factors (hypertension, ischaemia, obesity) remains unclear.
We aimed to determine the prevalence of SA in HF and to identify potential risk factors for SA in HF population.
Methods: We prospectively evaluated 103 patients with stable HF on optimized therapy. In-laboratory
polysomnography was performed. Type and severity of SA were defined according international criteria.
Demographic, anthropometric and clinical characteristics were collected. Continuous data are expressed as median
and interquartile range.
Results: SA was found in 72.8%, moderate to severe in a significant proportion (apnoea-hypopnoea index ≥ 15-
44.7% of all patients) and predominantly obstructive (60.0% of patients with SA). Most patients were non-sleepy
(Epworth < 10- 66%). SA patients were predominantly men (85.3 vs 60.7%, p-0.015), had larger neck (38.0 (35.0-
42.0) vs 35.0 (33.2-38.0) cm, p-0.003), severe systolic dysfunction, (63.9 vs 33.3%, p-0.018), left ventricle (LV)
hypertrophy (16.2 vs 0.0%, p-0.03), LV and left atria (LA) dilatation (49.0 (44.0-52.0) vs 42.0 (38.0-48.0) mm, p < 0.001;
60.0 (54.0-65.0) vs 56.0 (52.0-59.0) mm, p-0.01). However, only LA diameter was an independent predictor of SA.
Higher body-mass index (BMI) was associated with moderate to severe SA. Patients with obstructive SA had larger
neck and a trend for higher BMI, snoring and sleepiness. Hypocapnia was not associated with central SA.
Conclusions: In our HF population, SA was prevalent, frequently asymptomatic and without characteristic risk
factors. Unlike previously reported, obstructive SA was the predominant type. These results suggest that SA is
underdiagnosed in HF and there is a possible correlation between them, independent of confounding factors.
Recent advances in HF therapy might influence prevalence and type of SA in this population.
Background
Heart failure (HF) and sleep apnoea (SA) are prevalent,
have significant morbimortality and a huge economic
burden, making them public health problems [1-5].
SA has been associated with cardiovascular disease
[6-8] and an independent correlation has been estab-
lished with hypertension [9]. However, there is less evi-
dence for HF [10-18]. A high prevalence of SA has been
reported in HF populations (40-70%) but there is a
limited number of studies and different diagnostic cri-
teria and methods were used [7,13-18]. They evaluated
heterogeneous populations, with small number of
patients, mainly men. Also, there are several confound-
ing factors (hypertension, ischaemic heart disease, obe-
sity), making difficult to establish an independent
relationship [10-12].
Most studies have described an association between
HF and central type of SA [15,16,19-21]. It has been
suggested that central SA may be a consequence of HF
rather than a cause and it could be improved with opti-
mization of HF therapy [19]. Obstructive SA has been
considered a cardiovascular risk factor [6,7].
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hood of having HF (OR 2.38, 95%CI 1.22-4.62) [7] and
may be associated with worse outcome [20-22].
HF continues to be devastating despite advances in
pharmacotherapy [3,4]. It is crucial to identify and treat
comorbidities which may contribute to its progression.
HF studies have focused in the awake patient, probably
because sleep has been seen as a cardiovascular rest
state [10-12]. However, SA interrupts it and may contri-
bute for progression of HF by several mechanisms: acti-
vation of neurohumoral systems (sympathetic, renin-
angiotensin, natriuretic peptides); recurrent hypoxemia
leading to myocardial ischaemia; successive negative
deflections in intrathoracic pressure leading to afterload
increase, preload decrease and lower stroke volume;
inflammatory activation, prothrombotic state and
endothelial dysfunction [10-12]. Standard treatment for
SA (CPAP) has been shown to improve symptoms and
cardiac function in HF, but there is conflicting results
on its impact on prognosis [23,24].
The aims of this study were to determine the preva-
lence of SA in a stable HF population, diagnosed and
treated according updated international recommenda-
tions [1,2]. To evaluate the characteristics of HF patients
with SA which may help to identify the population at
risk in clinical practice.
Methods
Patients and study protocol
Between March 2005 and July 2007, 103 patients were
consecutively recruited from a HF clinic, in an university
hospital.
They had to be stable and on optimized therapy for
inclusion in the study. HF was defined according to the
European Society of Cardiology [1]. Patients were con-
sidered stable if there were no changes in New York
Heart Association (NYHA) class or medications within
the last month. Exclusion criteria were: unstable HF;
acute coronary syndrome in the previous 3 months; pre-
vious diagnosis of SA or hypoventilation syndrome;
treatment with positive pressure ventilation (CPAP or
BiPAP) in the previous 3 months. Only 5 patients were
excluded because they were already on non-invasive
ventilation.
Each patient was evaluated and completed Epworth
Sleepiness Scale (ESS) which is validated in Portuguese
language [25]. Anthropometric features were recorded
by the same observer during the study (body-mass index
(BMI), waist/hip, neck circumference, thyromental dis-
tance and Mallampati classification). Mallampati scoring
is a simple non-invasive method to assess the airway. It
is commonly used by the anesthesiologists to predict the
difficulty of endotracheal intubation, but it has been
correlated with the presence and severity of obstructive
SA [26].
Polysomnography was performed, using a multichan-
nel polygraph (SomnoStar CephaloPro, SensorMedics®),
monitored and manually scored by two technicians who
w e r et h es a m ed u r i n ga l lt h es t u d y .W er e c o r d e de l e c -
tro-encephalogram, electro-oculogram, submental elec-
tromyogram, heart rate and body position. Thoraco-
abdominal excursions were registered using respiratory
inductive plethysmography. Nasal airflow was measured
using a thermocouple and nasal pressure transducer.
Oxyhemoglobin saturation was recorded using a pulse
oximeter.
The following tests were also obtained: complete
blood count and biochemistry, plasma NT-proBNP
levels (immunoassay DadeBehring®), arterial blood gas
and spirometry (in the morning following polysomno-
graphy). Echocardiography was standardized across all
patients and time separation between polysomnography
and echocardiography was 6 months to 1 year.
This protocol was approved by the local ethics com-
mittee and patients signed an informed consent form.
Diagnosis and classification of sleep apnoea
Sleep apnoea was defined according to the American
Academy of Sleep Medicine [27]. An apnoea was
defined as complete cessation of inspiratory flow for 10
seconds or more. Hypopnoea was defined as a reduction
of airflow or thoraco-abdominal excursions lasting 10
seconds or more and associated with at least 4% drop in
oxygen saturation and/or arousal. An arousal was
defined as appearance of alpha-waves on electro-ence-
phalogram for at least 3 seconds. Obstructive SA was
defined as the absence/reduction of airflow in the pre-
sence of thoraco-abdominal excursions. Central SA was
defined by absence of respiratory effort. Cheyne-Stokes
respiration was considered in the presence of at least
three consecutive cycles of a cyclical crescendo-decres-
cendo change in breathing amplitude.
Severity of SA was defined according to the number of
apnoeas and hypopnoeas per hour of sleep - apnea-
hypopnea index (AHI): 5-14 - mild; 15-29 - moderate;
≥ 30 - severe.
Type of SA was defined according to the most preva-
lent events: ≥ 50% obstructive - obstructive SA; ≥ 50%
central - central SA; no prevalent type - mixed. Sleep
studies were also scored to assess the presence of
Cheyne-Stokes respiration.
Data analysis
We determined the total prevalence of SA in our HF
population and according to severity and type of SA.
Given the small number of patients with pure central
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to patients with mixed type.
We compared the characteristics of patients without
SA (AHI < 5) and: with SA (AHI ≥ 5); with moderate to
severe SA (AHI ≥ 15); with obstructive SA; with central/
mixed SA.
Continuous variables were reported as median and
interquartile range and Mann-Whitney test was used for
comparison between two groups. For categorical vari-
ables, c
2 or Fisher test were used. Multiple logistic
regression was used to identify the variables that were
independently associated with the presence of SA.
p value < 0.05 was considered significant.
Results
Prevalence and type of sleep apnoea
According to the defined criteria, there were 75 patients
(72.8%) with SA (AHI ≥ 5) and 44.7% had moderate to
severe SA (AHI ≥ 15) (Figure 1). The median AHI was
17.6/hour (9.3-42.5). Among patients with SA, most had
moderate to severe SA (61.3%, n = 46), with median
AHI of 40.4 (26.8-61.2). A significant proportion had
severe SA (n = 30, 40% of patients with SA and 29.1%
of all patients) (Figure 1).
Obstructive SA was the most prevalent type (60.0%,
n = 45) and only 9.3% of patients (n = 7) had pure cen-
tral SA (Figure 2). Both types of SA (mixed SA) were
present in 23 patients (30.7%) (Figure 2). Cheyne-Stokes
respiration was noted in 19 patients (25.6%), indepen-
dently of the predominant type of SA.
Patients characteristics and comparison between groups
Patients characteristics are shown in Tables 1, 2 and 3
(in the additional files section).
According to the severity of sleep apnoea
Patients with SA (AHI ≥ 5) were predominantly men.
They had larger neck, but no other significant differ-
ences in craniofacial characteristics. Total population
was overweight but BMI was not associated with SA.
Most patients were non-sleepy (ESS < 10-66%) and
snoring but there was a trend toward higher ESS score
and snoring in patients with SA (Table 1).
More than half of patients had severe left ventricular
systolic dysfunction but it was more prevalent in
patients with SA. Hypertension was equally prevalent,
but left ventricle hypertrophy (LVH), left ventricle (LV)
and atria (LA) dilatation were more common in patients
with SA. There were no significant differences in pul-
monary arterial pressure and right heart dilatation
despite higher values were noted in the SA group
(Table 2). Most patients were optimally treated accord-
ing international recommendations and there were no
significant differences between patients with and with-
out SA: furosemide - 95.1%, 76.3 ± 44.2 mg; ACE-inhi-
bitors - 95.1%, 13.0 ± 9.0 mg (lisinopril equivalent);
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Figure 1 Prevalence and severity of sleep apnoea in heart failure. AHI- apnoea-hypopnoea index.
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Figure 2 Type of sleep apnoea in heart failure.
Table 1 Risk factors for sleep apnoea in heart failure.
Total (N = 103) With SA (N = 75) Without SA (N = 28) p value
Age (years) 66.0 (57.0-75.0) 66.0 (57.0-75.0) 67.5 (60.2-74.8) 0.70
Male (%) 78.6 85.3 60.7 0.015
BMI (Kg/m
2) 27.2 (23.6-30.8) 27.0 (24.0-31.0) 27.4 (22.5-29.6) 0.25
Waist/hip 0.97 (0.92-1.00) 0.98 (0.92-1.02) 0.96 (0.93-1.0) 0.32
Neck circumference (cm) 37.0 (35.0-41.0) 38.0 (35.0-42.0) 35.0 (33.2-38.0) 0.003
Thyromental distance (cm) 7.0 (6.0-8.0) 7.0 (6.0-8.0) 7.0 (5.2-8.0) 0.56
Mallampati C-D (%) 58.3 60.3 53.6 0.70
Smoking (%) 51.5 53.3 46.4 0.69
Drinking (%) 41.7 46.7 28.6 0.15
Snoring (%) 71.8 77.3 57.1 0.08
ESS (score) 5.5 (2.8-10.0) 7.0 (3.0-10.0) 4.0 (1.0-9.0) 0.08
AHI- apnoea-hypopnoea index; BMI- body-mass index; ESS- Epworth sleepiness scale.
Continuous data are expressed as median and interquartile range.
Table 2 Cardiovascular characteristics in heart failure patients with and without sleep apnoea.
Total (N = 103) With SA (N = 75) Without SA (N = 28) p value
Hypertension (%) 55.3 56.0 53.6 1.00
Ischaemic aetiology (%) 54.4 54.7 53.6 1.00
Atrial fibrillation (%) 34.3 36.5 28.6 0.60
NYHA II-III vs I (%) 61.8 67.6 46.4 0.08
Echocardiography
Severe LVSD (%) 56.3 63.9 33.3 0.018
LVH (%) 12.1 16.2 0.0 0.03
LVEDD (mm) 59.0 (54.0-64.3) 60.0 (54.0-65.0) 56.0 (52.0-59.0) 0.01
LA (mm) 47.0 (41.0-51.0) 49.0 (44.0-52.0) 42.0 (38.0-48.0) < 0.001
PSAP (mmHg) 48.0 (40.0-52.8) 50 (40-53) 45 (38-52) 0.46
NT-proBNP (pg/mL) 1260.6 (552.3-2493.2) 1317.6 (705.9-2218.9) 1137.7 (232.9-2718.2) 0.51
AHI- apnoea-hypopnoea index; NYHA- New York Heart Association; LVSD- left ventricle systolic dysfunction; LVH- left ventricle hypertrophy; LVEDD- left ventricle
end-diastolic diameter; LA- left atria; PSAP- pulmonary systolic arterial pressure; RV- right ventricle.
Continuous data are expressed as median and interquartile range.
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equivalent); spironolactone - 42.7%, 7.9 ± 12.9 mg.
Sleep efficiency was low but it was not significantly
different between patients with and without SA (52.0 vs
57.0%, p-0.67). More than half of all patients had
obstructive syndrome (FEV1/FVC < 70%- 55.1%) but
prevalence was not significantly different in patients
with and without SA (59.2 vs 44.4%, p-0.28). Patients
with SA had more nocturnal desaturation and lower
oxygen saturation (Table 3), despite having similar and
normal awake blood gases (PaO2- 81.8 (73.6-90.6) vs
81.6 (76.0-87.2), p-0.87; PaCO2- 41.0 (37.7-43.6) vs 41.7
(39.2-44.2) mmHg, p-0.47).
When compared to patients without SA, those with
moderate to severe SA (AHI ≥ 15) were similar to
patients with AHI ≥ 5: predominantly men- 91.3 vs
60.7%, p-0.004; larger neck - 38.0 (35.0-44.0) vs 35.0
(33.2-38.0) cm, p-0.003; severe LV systolic dysfunction-
68.2 vs 33.3%, p-0.01; LV and LA dilatation: LV end-dia-
stolic diameter- 61.0 (57.0-65.0) vs 56.0 (52.0-59.0) mm,
p-0.008; LA diameter- 49.0 (44.0-52.0) vs 42.0 (38.0-48.0)
mm, p < 0.001; more light sleep: stage 1- 20.0 (13.5-32.7)
vs 11.6 (5.4-15.3) %, p < 0.001, sleep stages 3 and 4- 2.7
(0.0-10.4) vs 19.3 (13.4-31.5) %, p < 0.001. However,
higher BMI was also associated with moderate to severe
SA (29.1 (25.7-33.5) vs 27.4 (22.5-29.6) Kg/m
2, p-0.05).
In multivariate analysis, when adjusted for gender,
BMI, neck circumference, NYHA class II-III, severe sys-
tolic dysfunction, LV diastolic diameter and LA dia-
meter per body surface, only LA diameter (each
milimeter increase) was an independent predictor of SA
in HF patients (OR 1.11, 95%CI 0.99-1.26). Male gender,
BMI and NYHA class II-III were independent predictors
of moderate to severe SA (respectively: OR 6.70, 95%CI
1.64-27.28; OR 1.12, 95%CI 1.02-1.24; OR 2.97, 95%CI
1.08-8.17).
According to the type of sleep apnoea
When compared to patients without SA, those with
obstructive type had larger neck (39.0 (35.0-43.5) vs 35.0
(33.2-38.0) cm, p-0.002). There was a trend for higher
BMI (29.1 (24.5-33.3) vs 27.4 (22.5-29.6), p-0.09), snor-
ing (80.0 vs 57.1%, p-0.07) and higher ESS score (ESS- 7
(4.0-12.0) vs 4 (1.0-9.0), p-0.07).
Patients with central/mixed SA were predominantly
men (96.7 vs 60.7, p-0.002) and had a trend for larger
neck (36.0 (35.0-40.0) vs 35.0 (33.2-38.0) cm, p-0.05).
Severe LV systolic dysfunction was significantly asso-
ciated with obstructive SA and there was a trend for an
association with central/mixed SA (respectively: 66.7%,
p-0.02; 60.0%, p-0.09). LA diameter was related to both
types of SA (obstructive- 48 (43.5-53.0) mm, p-0.002;
central/mixed- 49.0 (44.5-51.5) mm, p-0.001).
When we compared different patterns of SA
(obstructive vs central/mixed SA), patients with
obstructive SA had a trend for higher BMI (29.1 (24.5-
33.3) vs 26.1 (23.4-29.2) Kg/m
2,p - 0 . 0 8 ) .D e s p i t et h e y
had larger neck than patients without SA, their neck
circumference was not significantly different from
patients with central/mixed SA (39.0 (35.0-43.5) vs
36.0 (35.0-40.0) cm, p-0.16). Other craniofacial charac-
teristics were also similar (Mallampati C and D- 60.0
vs 60.7%, p-1.0; thyromental distance- 7.0 (6.0-8.0) vs
7.0 (6.0-8.0) cm, p-0.41). Snoring was equally prevalent
(80.0 vs 73.3%, p-0.19).
Patients with central/mixed pattern had more severe
SA (AHI-32.9 (10.8-71.9) vs 15.7 (8.9-29.6), p-0.02) and
shorter total sleep time (215.5 (175.0-247.0) vs 278.5
(228.5-354.5) minutes, p-0.001). They were significantly
older (72.0 (62.8-78.2) vs 63 (53.5-70.5) years, p-0.008)
and mostly men (96.7 vs 77.8%, p < 0.001). Ischaemic
aethiology was more prevalent in this group (70.0 vs
44.4%, p-0.015).
Table 3 Sleep characteristics in heart failure patients with and without sleep apnoea
Total (N = 103) With SA (N = 75) Without SA (N = 28) p value
AHI (n/h) 10.4 (4.6-30.5) 17.6 (9.3-42.5) 1.9 (0.6-4.1) < 0.001
Total sleep time (TST, min) 246.0 (189.5-333.0) 246.2 (189.5-334.0) 222.0 (131.5-301.5) 0.34
Sleep (% TST)
Stage 1 15.5 (10.0-23.4) 17.5 (12.7-27.4) 11.6 (5.4-15.3) < 0.001
Stage 2 60.4 (49.8-71.2) 60.4 (50.3-72.0) 60.9 (46.6-70.4) 0.58
Stages 3 and 4 10.9 (1.0-20.3) 6.9 (0.3-15.1) 19.3 (13.4-31.5) < 0.001
REM 8.0 (3.1-12.7) 8.4 (3.8-13.1) 6.4 (0.0-10.9) 0.17
NREM 92.1 (87.4-97.2) 91.6 (87.1-96.4) 93.6 (89.100.0) 0.22
Arousals (n/h) 6.1 (3.1-10.4) 7.2 (4.0-11.0) 3.8 (1.0-7.3) 0.02
Mean SO2 (%) 93.0 (91.0-95.0) 93.0 (90.0-94.0) 94.0 (92.0-96.0) 0.02
Lowest SO2 (%) 81.0 (76.0-85.0) 81.0 (71.2-85.0) 85.0 (79.0-88.0) 0.006
SO2 < 90% (% TST) 7.7 (2.0-27.6) 15.6 (3.7-39.8) 2.0 (0.2-6.2) < 0.001
AHI- apnoea-hypopnoea index; SO2- oxyhemoglobin saturation.
Continuous data are expressed as median and interquartile range.
Ferreira et al. BMC Pulmonary Medicine 2010, 10:9
http://www.biomedcentral.com/1471-2466/10/9
Page 5 of 8Severe LV systolic dysfunction was not associated to a
specific pattern of SA (obstructive- 66.7 vs central/
mixed- 60.0%, p-0.28). Spironolactone was more often
prescribed in patients with obstructive SA (51.1 vs
33.3%, p-0.02). Other therapies were similar in the two
groups.
Discussion
In this prospective study of well-defined, severe, stable
HF outpatients, on optimized therapy, we found a high
prevalence of SA (AHI ≥ 5- 72.8%, AHI ≥ 15- 44.7%),
independent of clinical suspicion or symptoms (ESS <
10- 66%). This emphasizes the relevance of the associa-
tion between those public health problems and question
the need for screening of SA in HF population.
It is in agreement with previous studies, but there is a
high variability in the reported prevalence of SA in HF
(40-70%) [13-18]. Possible explanations are the small
number of patients involved in most studies, predomi-
nantly men, the heterogeneity of populations and the
different used diagnostic criteria and methods. Our
study is one of the largest in this area, using more
recent sleep sensors technology and international diag-
nostic criteria [27]. It reports data from a heart failure
clinic, including patients with significant comorbidities.
Most patients were referred to the clinic after an acute
HF episode. These patients, although not representative
of the general population, have some characteristics
similar to Heart Failure in the general population. Epi-
demiological studies performed in Portugal and Spain
reported a medium age of 64 and 65 years in Heart Fail-
ure patients [28,29]. Our study included 55% of patients
older than 65 years (mean age 66 years), higher than
other studies previously published [13-18]. Mared et al
reported a high prevalence of Cheyne-Stokes respiration
in an older HF population (mean age 73 years) [30].
However, patients were hospitalised for decompensated
HF and not stable and ambulatory as in our study.
Unlike previously reported, in our HF population, SA
was predominantly obstructive.
Central SA has been seen as a consequence of HF,
correlated with its severity and prognosis [19-21]. How-
ever, this could not explain our results since we had a
high prevalence of severe LV systolic dysfunction in the
total population (56.3%), significantly associated with SA
(63.9 vs 33.3, p-0.018) but not to central/mixed type.
Also, in contrast to other studies [15,16], SA was predo-
minantly obstructive (60%). Only 9.3% of patients had
pure central SA and a significant proportion had both
types (30.7%).
Despite the severity of HF, patients were stable and on
optimized therapy which could contributed to lower the
prevalence of central SA in our study. The management
of HF has evolved in last decade, with widespread use of
ACE-inhibitors and beta-blockers [1-4]. The new phar-
macotherapy has significantly improved prognosis of HF
[3,4], but the impact in the prevalence and type of SA
has not been evaluated [16,17,31,32]. Two recent studies
have shown that HF patients taking beta-blocker have a
lower prevalence and severity of SA [31,32]. In contrast
to some of the previous studies, our patients were
receiving optimal treatment for HF (beta-blocker-
90.3%, ACE-inhibitors- 95.1%, spironolactone- 42.7%).
In some of the studies that reported predominance of
central SA, use of beta-blocker was lower (10 and 78%)
[15,16].
Javaheri et al studied 100 patients with severe stable
HF [15]. Prevalence of moderate to severe SA (AHI ≥
15) was similar to our population (49.0 vs 44.7%) but
central SA was the predominant type (37.0 vs 12.0%).
However, only men were included and the investigation
started in nineties, when current HF therapy was not
widespread (beta-blocker-10%, ACE-inhibitors- 91%).
More recently, Vazir et al reported similar results [16]
in a HF population with improved treatment (beta-
blocker- 78%, ACE-inhibitors- 98%, spironolactone-
49%).
Nevertheless, other studies found a high proportion of
obstructive SA, in according to our results [14,17,18]. In
a population of 53 outpatients with stable HF, preva-
lence of SA (AHI > 10) was 68%, predominantly
obstructive (53%) [14]. Oldenburg et al studied 700
patients and found 76% prevalence of SA (AHI ≥ 5),
36% obstructive [17]. Schulz and colleagues studied 203
patients and reported a prevalence of 71% (AHI > 10),
43% obstructive [18]. In the two last studies, diagnosis
was based in polygraphy which can underestimate AHI.
A sac o n s e q u e n c e ,t h ep r e v a l e n c ea n ds e v e r i t yo fS A
might even be higher.
Our patients were overweight which could contribute
to the predominance of obstructive SA. However, BMI
was not different in patients with and without SA and
median BMI was similar to studies where central SA
was predominant [15,16]. Neck circumference was sig-
nificantly greater in patients with SA which could con-
tribute to the predominance of the obstructive type.
Ferrier et al studied a HF population with a larger neck
(41.0 vs 37.0 cm) and found similar results [14]. Cranio-
facial anthropometric characteristics were not men-
tioned in other studies [13,15-18].
Characteristics that could help to identify HF patients
with SA have been described: male gender for both
types of SA; age > 60 years, atrial fibrillation and hypo-
capnia for central SA; for obstructive SA, higher BMI in
men and age > 60 years in women [13]. However, this
study was retrospective, patients were recruited from a
population referred for suspected SA and asymptomatic
patients were excluded. In the study by Javaheri et al,
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tion and hypocapnia were associated with central SA
[15]. Obesity and snoring were risk factors for obstruc-
tive SA. Similar results were reported by other authors
[14,16,17].
We did not find characteristic risk factors for SA in
patients with HF. Male gender, larger neck, severe systo-
lic dysfunction, LV hypertrophy, LV and LA dilatation
were significantly associated with SA. However, in mul-
tivariate analysis, only LA diameter was an independent
predictor of SA. Its significance is uncertain, but LA
dilatation could be an early marker of hypertension and
diastolic dysfunction which have been independently
associated with SA [9].
Patients with obstructive SA had larger neck and a
trend for higher BMI, snoring and higher ESS score
which is in agreement with literature [13]. Patients with
central/mixed SA were predominantly men and older.
Unlike previously reported [13,15], awake hypocapnia
was not associated with central SA.
As previously described [14], in our population NT-
proBNP levels were not different in all groups but
patients with SA had more severe LV systolic dysfunc-
tion. Severe systolic dysfunction was not associated to a
specific pattern of SA. Other authors found higher levels
of NT-proBNP in patients with SA but no difference in
LV systolic dysfunction [16].
In our study, sleep efficiency was unsatisfactory. This
could be explained by the “first-night effect”,r e s u l t i n g
from insomnia related to a different environment.
However, as sleep efficiency was not different in
patients with or without SA, it didn’ti n t e r f e r ew i t ht h e
results.
Patients with SA had more sleep fragmentation and
nocturnal desaturation but not increased daytime sleepi-
ness, in accordance with other studies [15-18]. This sug-
gests that subjective daytime sleepiness measured by
ESS is not useful in screening of SA in HF patients, but
deleterious effects of inefficient sleep are present.
We are aware of some limitations to our study. The
number of patients in each group is relatively small but,
to our knowledge, it is one of the largest studies in the
literature. Other studies involved a much larger number
of patients but they were retrospective and in a HF
population with suspected SA [13]. Unlike in our study,
diagnosis was based in polygraphy [17,18] which is not
still validated in HF population [33]. The small number
of patients with pure central SA and its association with
mixed type, could limit interpretation of data.
Conclusions
Prevalence of sleep apnoea was high in patients with
stable HF despite optimized therapy (72.8%). Most were
non-sleepy (ESS < 10- 66%). Unlike has been usually
reported, obstructive SA was the predominant type
(60%). Male gender, larger neck, severe systolic dysfunc-
tion, LV hyperthrophy, LV and LA dilatation were asso-
ciated with SA but only LA diameter was an
independent predictor.
These results suggest that SA is underdiagnosed in HF
because it is frequently asymptomatic and characteristics
risk factors are not present in most patients. There is a
possible correlation between HF and SA independent of
most known confounding factors. Recent advances in
HF therapy which improve cardiac function and out-
come might influence prevalence and type of SA in this
population. If standard treatment for SA is shown to
improve prognosis in patients with HF, screening would
be recommended.
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